Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Sanjay K Jain, M.D.

Johns Hopkins University

Intervention

18F-Pretomanid PET/CT(combination_product)

Enrollment

10 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2025

Study locations (1)

• Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07164742
  Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
  Johns Hopkins University
• RECRUITINGNCT07077213
  18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
  Children's Hospital Medical Center, Cincinnati
• RECRUITINGNCT07451899
  TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
  Universitas Padjadjaran
• RECRUITINGNCT06845618
  Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
  University of Oxford
• ENROLLING BY INVITATIONNANCT06984887
  Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
  Mercy Corps Pakistan
• RECRUITINGNCT07018076
  Candidate Clinical Correlate of Prognostic Outcome for TB Study
  University of California, San Francisco
• RECRUITINGNANCT07271225
  Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
  Indonesia University
• RECRUITINGNCT06585358
  DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
  Karolinska Institutet

See all trials for Tuberculosis →